Training activity information
Details
Analyse the appropriate genetic tests for pharmacogenetic testing in oncology patients, to include:
- DPYD
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the established clinical guidelines for requesting DPYD pharmacogenetic testing in oncology patients prior to treatment with specific drugs?
- What patient information (e.g., planned treatment regimen, previous adverse drug reactions) is essential to determine if a DPYD testing referral is appropriate?
- What are some circumstances where DPYD testing might not be indicated or might need to be prioritised based on clinical urgency?
- How will you develop your ability to assess referral information and determine if DPYD testing is justified based on current guidelines?
- Will you review relevant pharmacogenetic guidelines and discuss clinical scenarios with your training officer or a clinical pharmacist?
- What specific referral examples will you consider to understand the factors that influence the appropriateness of DPYD testing?
- What potential challenges might you encounter when analysing the appropriateness of a DPYD testing referral (e.g., incomplete treatment information, requests for testing outside of guidelines)? How might you address these?
In action
- How are you currently approaching the analysis, and what real-time decisions are you making to translate specific genotypes or diplotypes into predicted enzyme activity and dose recommendations?
- What challenges are you encountering in this moment—such as interpreting complex genotypes or novel variants—and how effectively are you linking these findings to the risk of severe chemotherapy toxicity?
- How are you managing uncertainty or complexity, for instance by consulting pharmacogenetic resources or seeking expert advice, to ensure your analysis adheres to established guidelines for personalized cancer treatment?
On action
- What DPYD genotypes were identified in the samples you analysed?
- How were these genotypes correlated with predicted enzyme activity and potential risk of toxicity?
- Were there any cases where the genotype-phenotype correlation was not straightforward?
- Did you improve your ability to analyse pharmacogenetic data for DPYD?
- Did you learn about the different DPYD allele nomenclature and their functional consequences?
- How are pharmacogenetic test results translated into clinical recommendations for drug dosage or alternative therapies?
- What resources will you use to ensure accurate analysis and interpretation of pharmacogenetic test results?
- How will you stay updated on the clinical guidelines and recommendations for pharmacogenetic testing in oncology?
- How will you contribute to the appropriate implementation of pharmacogenetic testing in clinical practice?
Beyond action
- Reflecting on your initial experiences analysing pharmacogenetic data for oncology patients, particularly DPYD, how has your understanding of the relationship between genotype and phenotype in drug metabolism evolved?
- Have you encountered cases where the analysis of pharmacogenetic markers has been particularly challenging or has required consultation with clinical colleagues? What did you learn from these experiences?
- How have the analytical skills developed here been applicable to your analysis of other pharmacogenetic markers or in different clinical contexts?
- As the field of pharmacogenomics continues to grow, how will your foundational analytical skills prepare you to interpret and apply new pharmacogenetic information in clinical practice?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 6 |
Outcome
Analyse, interpret and report pharmacogenetic testing in oncology patients. |